Because PARP1 represents an attractive target for MM therapy and Ma et al. predicted that PARP1 was a potential target of bufalin via the molecular docking method [25], we investigated whether bufalin can target PARP1 and exert its anti-myeloma activity. This evidence concerns the gene PARP1 and plasma cell myeloma.